期刊文献+

左西孟旦与多巴酚丁胺在难治性心力衰竭治疗中的对比研究 被引量:12

原文传递
导出
摘要 目的评价左西孟旦与多巴酚丁胺治疗难治性心力衰竭的临床疗效及不良反应。方法选择难治性心力衰竭患者70例,采用随机、对照的方法,分为治疗组(35例)和对照组(35例),两组基础治疗相同,治疗组给予左西孟旦治疗(剂量为0.05~0.2μg·kg-1·min-1),对照组给予多巴酚丁胺治疗(剂量为2~10μg·kg-1·min-1),治疗时间为7d。观察治疗前后两组心脏功能及血清脑利钠肽(BNP)指标的变化。结果与对照组相比,治疗组心功能改善更加明显(P〈0.05),BNP明显降低(P〈0.01)。结论与多巴酚丁胺相比,左西孟旦治疗难治性心力衰竭疗效确切,显示出相对于其他传统正性肌力药物的优越性。
出处 《中华临床医师杂志(电子版)》 CAS 2015年第18期96-98,共3页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献8

  • 1白玲,马爱群.急性心力衰竭诊断和治疗展望[J].心血管病学进展,2011,32(4):465-469. 被引量:27
  • 2Dao Q,Krishnaswamy P,Kazanegra R,et al.Utilty of B-type natriuretic peptide in the diagnosis of congestive heart failure from lung disease in patients presenting with dyspnea[J].J Am Coll Cardial,200l,37(2):379-385.
  • 3Dec GW.Acute decompensated heart failure:the shrinking role of inotropic therapy[J].J Am Coll Cordial,2005,46(1):65-67.
  • 4纪木火,李仁奇,张庆伟,杨建军.钙增敏剂左西孟旦的研究进展[J].药学与临床研究,2010,18(5):458-461. 被引量:12
  • 5Cleland JG,Freemantle N,Coletta AP,et al.Clinical trials update from the American Heart Association:REPAIR-AMI,ASTAMIJELIS,MEGA,REVIVE-II,SURVIVE,and PROACTIVE[J].Eur J Heart Fail,2006,8(1):105-110.
  • 6Franco F,Goncalves F,Castro G,et al.Levosimendanis efficacious in acute heart failure in dependent of rena1 function[J].Eur Heart J,2003,24(suppl):408.
  • 7Morelli A,Decastro S,Teboul JL,et al.Effects of levosimendanon systemic and regional hemodynamics inseptic myocardial depression[J].Intensive Care Med,2005,31(5):638-644.
  • 8Sharma M,Teerlink JR.A rational approach for the treatment of acute heart failure:current strategies and future options[J].Curr Opin Cardiol,2004,19(3):254-263.

二级参考文献66

  • 1Ukkonen H,Saraste M,Akkila J,et al.Myocardial efficiency during levosimendan infusion in congestive heart failure[J].Clin Pharmacol Ther,2000,68(5):522-31.
  • 2Nanas JN,Papazoglous PP,Terrovitis JV,et al.Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone[J].Am J Cardiol,2004,94(10):1329-32.
  • 3Erbuyun K,Vantansever S,Tok D,et al.Effects of levosimendan and dobutamine on experimental acute lung injury in rats[J].Acta Histochem,2009,111(5):404-14.
  • 4Antila S,Jarvinen A,Honkanen T,et al.Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin[J].Eur J Clin Pharmacol,2000,56(9-10):705-10.
  • 5Kivikko M,Lehtonen L,Colucci WS,et al.Sustained hemodynamic effects of intravenous levosimendan[J].Circulation,2003,107(1):81-6.
  • 6Sorsa T,Pollesello P,Rosevear PR,et al.Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization[J].Eur J Pharmacol,2004,486(1):1-8.
  • 7Kopustinskiene DM,Pollesello P,Saris NE,et al.Potassium-specific effects of levosimendan on heart mitochondria[J].Biochem Pharmacol,2004,68(5):807-12.
  • 8Maytin M,Colucci WS.Cardioprotection:a new paradigm in the management of acute heart failure syndromes[J].Am J Cardiol,2005,96(6A):26-31.
  • 9Szilagyi S,Pollesello P,Levijoki J,et al.The effects of levosimendan and OR-1896 on isolated hearts,myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig[J].Eur J Pharmacol,2004,486(1):67-74.
  • 10Brixius K,Reicke S,Schwinger RH,et al.Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium[J].Am J Physiol Heart Circ Physiol,2002,282(1):131-7.

共引文献37

同被引文献109

引证文献12

二级引证文献122

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部